Today, Eiger BioPharmaceuticals’ (EIGR) “Outperform” Rating Reiterate at Oppenheimer Holdings Inc.

Today, Eiger BioPharmaceuticals’ (EIGR) “Outperform” Rating Reiterate at Oppenheimer Holdings Inc.

Oppenheimer Holdings Inc. restated their outperform rating on shares of Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) in a research note released on Monday morning. They currently have a $34.00 target price on the stock.

Several other equities research analysts have also commented on the company. Jefferies Group restated a buy rating and issued a $33.00 price objective on shares of Eiger BioPharmaceuticals in a research note on Thursday, October 20th. Wedbush restated an outperform rating and issued a $36.00 price objective (up from $34.00) on shares of Eiger BioPharmaceuticals in a research note on Tuesday, November 8th. Finally, Zacks Investment Research lowered Eiger BioPharmaceuticals from a hold rating to a sell rating in a research note on Thursday, November 10th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $34.00.

Shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) opened at 12.75 on Monday. The firm’s 50-day moving average price is $12.45 and its 200 day moving average price is $16.69. Eiger BioPharmaceuticals has a 52 week low of $10.71 and a 52 week high of $28.35. The company’s market cap is $106.54 million.

In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn purchased 15,460 shares of the business’s stock in a transaction on Friday, November 18th. The stock was acquired at an average price of $12.74 per share, for a total transaction of $196,960.40. Following the purchase, the director now owns 16,355 shares of the company’s stock, valued at approximately $208,362.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 27.20% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of EIGR. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Eiger BioPharmaceuticals during the first quarter worth about $251,000. Bank of New York Mellon Corp acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter worth about $214,000. California State Teachers Retirement System acquired a new stake in shares of Eiger BioPharmaceuticals during the second quarter worth about $144,000. Vanguard Group Inc. increased its position in Eiger BioPharmaceuticals by 265.6% in the second quarter. Vanguard Group Inc. now owns 124,787 shares of the company’s stock valued at $2,473,000 after buying an additional 90,659 shares during the period. Finally, BlackRock Investment Management LLC increased its position in Eiger BioPharmaceuticals by 4,942.9% in the second quarter. BlackRock Investment Management LLC now owns 12,355 shares of the company’s stock valued at $245,000 after buying an additional 12,110 shares during the period. Institutional investors and hedge funds own 39.95% of the company’s stock.

About Eiger BioPharmaceuticals

Related posts

Leave a Comment